



DEPOSITARY RECEIPTS

NEW DR ANNOUNCEMENT

May 22, 2014

Adocia

ADOCIA is a biotechnology company based in France. The Company specializes in the development of formulations for already-approved therapeutic proteins with a primary focus on insulins and treatments for diabetic foot ulcers. The Company's biotherapy products are used in tissue regeneration and for treating chronic diseases. The Company's proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins in areas such as wound Healing, diabetes, ulcers and monoclonal antibody creation. The Company also maintains activities in the formulation of monoclonal antibodies for the treatment of various chronic pathologies (oncology, inflammation, etc.).

Effective Date:	May 22, 2014
Country of Incorporation:	France
Exchange:	OTC
Type of ADR Program:	Sponsored - Level I
Ticker Symbol:	ADOCY
CUSIP Number:	00725J102
Ratio:	1:1
Underlying Share Description:	Common
Industry Classification:	Pharma. & Biotech.
Local Custodian(s):	Societe Generale (FR)

To learn more about ADRs and issuer programs, please call our marketing desks:

New York

Melissa Sobolewski/Ravi Davis
Adrdesk@bnymellon.com
Tel:212 815 2267

Hong Kong

Herston Powers
Vice President
herston.powers@bnymellon.com
Tel:852 2840 9868

London

Damon Rowan
Vice President
damon.rowan@bnymellon.com
Tel:442071637511

Depository Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon and are subject to investment risks including possible loss of principal amount invested.

This announcement and the information contain herein is provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this information. We provide no advice or recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. An offering is made by means of a prospectus only. BNY Mellon is regulated by the FSA.